Literature DB >> 16355325

Control and outcome of a large outbreak of colonization and infection with glycopeptide-intermediate Staphylococcus aureus in an intensive care unit.

Arnaud de Lassence1, Nadia Hidri, Jean-François Timsit, Marie-Laure Joly-Guillou, Guillaume Thiery, Alexandre Boyer, Pascale Lable, Annie Blivet, Helene Kalinowski, Yolaine Martin, Jean-Patrick Lajonchere, Didier Dreyfuss.   

Abstract

BACKGROUND: Glycopeptide-intermediate Staphylococcus aureus (GISA) is emerging as a cause of nosocomial infection and outbreaks of infection and colonization in intensive care units (ICUs). We describe an outbreak of GISA colonization/infection and the ensuing control measures in an ICU and investigate outcomes of the affected patients.
METHODS: We describe an outbreak of GISA colonization and infection that affected 21 patients in a medical ICU at a tertiary care teaching hospital, as well as the measures taken to eradicate the GISA strain. RESULT: Recognition of the outbreak was difficult. Infections, all of which were severe, were diagnosed in 11 of 21 patients. Patient isolation and barrier precautions failed when used alone. Addition of a stringent policy of restricted admissions, twice daily environmental cleaning, and implementation of hand decontamination with a hydroalcoholic solution led to outbreak termination. This was associated with increases in workload, despite a marked decrease in the number of admissions.
CONCLUSION: This first description of a large outbreak of GISA colonization and infection underlines the importance of routine GISA-strain detection when methicillin-resistant S. aureus is isolated. Outbreak control may be difficult to achieve.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16355325     DOI: 10.1086/498898

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  22 in total

1.  Antistaphylococcal activities of telavancin tested alone and in combination by time-kill assay.

Authors:  Gengrong Lin; Glenn A Pankuch; Lois M Ednie; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2010-02-16       Impact factor: 5.191

2.  Antistaphylococcal activity of DX-619 alone and in combination with vancomycin, teicoplanin, and linezolid assessed by time-kill synergy testing.

Authors:  Kim Credito; Genrong Lin; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2007-01-29       Impact factor: 5.191

3.  Activity of daptomycin alone and in combination with rifampin and gentamicin against Staphylococcus aureus assessed by time-kill methodology.

Authors:  Kim Credito; Gengrong Lin; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2007-01-12       Impact factor: 5.191

4.  Incidence and characteristics of vancomycin nonsusceptible strains of methicillin-resistant Staphylococcus aureus at Hershey Medical Center.

Authors:  Klaudia Kosowska-Shick; Lois M Ednie; Pamela McGhee; Kathy Smith; Cynthia D Todd; Amanda Wehler; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2008-10-06       Impact factor: 5.191

5.  Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay.

Authors:  Gengrong Lin; Lois M Ednie; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2010-02-09       Impact factor: 5.191

Review 6.  Controlling hospital-acquired infection: focus on the role of the environment and new technologies for decontamination.

Authors:  Stephanie J Dancer
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

7.  Lack of relationship between purine biosynthesis and vancomycin resistance in Staphylococcus aureus: a cautionary tale for microarray interpretation.

Authors:  Paige M Fox; Michael W Climo; Gordon L Archer
Journal:  Antimicrob Agents Chemother       Date:  2007-01-22       Impact factor: 5.191

8.  The MUT056399 inhibitor of FabI is a new antistaphylococcal compound.

Authors:  S Escaich; L Prouvensier; M Saccomani; L Durant; M Oxoby; V Gerusz; F Moreau; V Vongsouthi; Kirsty Maher; Ian Morrissey; C Soulama-Mouze
Journal:  Antimicrob Agents Chemother       Date:  2011-08-08       Impact factor: 5.191

9.  Activity of telavancin against staphylococci and enterococci determined by MIC and resistance selection studies.

Authors:  Klaudia Kosowska-Shick; Catherine Clark; Glenn A Pankuch; Pamela McGhee; Bonifacio Dewasse; Linda Beachel; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2009-07-20       Impact factor: 5.191

10.  Molecular features of heterogeneous vancomycin-intermediate Staphylococcus aureus strains isolated from bacteremic patients.

Authors:  Yasmin Maor; Levona Lago; Amir Zlotkin; Yeshayahu Nitzan; Natasha Belausov; Debby Ben-David; Nathan Keller; Galia Rahav
Journal:  BMC Microbiol       Date:  2009-09-04       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.